Phospho-Cardiac Troponin I (TNNI3)-S23/S24 Rabbit mAb for IHC-P, ELISA - P19429

Core Product Specifications and Parameters

Biological Background: Phospho-Cardiac Troponin I (TNNI3)-S23/S24 Function and Localization

• Cardiac troponin I (cTnI) is the inhibitory subunit of the troponin complex, which confers calcium sensitivity to striated muscle actomyosin ATPase activity, playing a central role in regulating cardiac muscle contraction.
• Encoded by the TNNI3 gene (also known as TNNC1), cTnI is specifically expressed in cardiac muscle and is a key thin filament regulatory protein.
• This antibody targets phosphorylation at serine residues S23 and S24, critical post-translational modifications that modulate cardiac contractility and are implicated in heart failure and cardiomyopathies (keywords: Phosphoprotein, Cardiomyopathy, Disease variant).
• As a cardiac-specific isoform, cTnI is a well-established clinical biomarker for myocardial injury (e.g., myocardial infarction), and its phosphorylation state can influence diagnostic assay performance.
• The protein contains actin-binding domains essential for its inhibitory function and interacts with troponin T and troponin C to form the functional troponin complex.
• UniProt keywords include Actin-binding, Muscle protein, and Proteomics identification, highlighting its structural role and significance in muscle physiology and disease.

Experimental Guidance and Technical Tips

• Given the phospho-specificity, validate the antibody’s reactivity using both phosphorylated and non-phosphorylated peptides or by treatment with phosphatases to confirm signal loss.
• For IHC-P applications, optimize antigen retrieval and use of phosphatase inhibitors may be critical to preserve the S23/S24 phosphorylation signal in tissue sections.
• In ELISA, consider pairing this antibody with a capture antibody against total cTnI to quantitatively assess phosphorylation stoichiometry in samples.
• Phosphorylation can be labile during sample collection and processing; ensure rapid handling and inclusion of phosphatase inhibitors to maintain in vivo modification states.
• Cross-reactivity has been confirmed for human; performance with other species should be validated experimentally if needed.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. This phospho-specific cardiac troponin I antibody supports cardiac biomarker assay development and signaling pathway research. CamelBio’s sourcing capabilities include validated antibody pairs, optimized monoclonal/polyclonal antibodies, and bulk ancillary reagents to accelerate your IVD assay development and commercialization.